Civorebrutinib

N/A

Report date: 2026/03/11 20:02:12
NME

Base Information

Drug NameCivorebrutinib
Drug Alias NameEVER001EVER-001XNW1011XNW-1011SN-1011 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsAutoimmune DiseasesPemphigusLupus Erythematosus, Systemic +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesEvopoint Biosciences Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesEverest Medicines (China) Co LtdEverest Medicines LtdSinolink Pharma (Suzhou) Ltd +[4] 
Inactive CompaniesSinomab Bioscience Ltd
Active IndicationsPemphigusLupus Erythematosus, SystemicNephrotic Syndrome +[7] 
Inactive IndicationsAutoimmune Diseases

Other Information

ATC CodeN/A
Related LinksN/A